A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

NCT03757000 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma Recurrent
B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG: YY-20394

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.